Associate Professor Darren Kelly
Principal Research Fellow
Research Training Director
| telephone | +61 3 9288 2592 |
| facsmilie | +61 3 9288 2581 |
| dkelly@medstv.unimelb.edu.au |
Profile
Research interests include anti-fibrotic therapies for the treatment of heart and kidney failure, diabetes, hypertension and drug discovery. Research Training Director for the St Vincent's Campus Cluster.
University of Melbourne find an expert profile
Professional Activities:
NHMRC grant review panel. Honorary Associate Professor (Bio21 Institute). Scientific Programming and Education Committee, ANZSN. Invited Member of the International Society of Pathology. Member: Australian Diabetes Society, Australian and New Zealand Society of Nephrology, European Association for the Study of Diabetes, American Diabetes Association, Australian Inst Company Directors. Invited Member of European Diabetic Nephropathy Study Group. Subject Editor Nephrology. Fellow of the ASN. CEO Fibrotech Therapeutics
Qualifications
B MedLSc FASN MSc PhD
Major Grants
- Novel therapeutic strategies to reduce the burden of chronic heart failure. (NHMRC Program Grant, 2005-2009, $4,634,965) H Krum, D Kelly, S Itescu.
- Prevention and Treatment of Chronic Heart and Kidney Disease via Epidemiological, Pharmacological Device and Cell-Based Approaches (NHMRC, Program Grant, 2010-2014 $5.4 Million AUD) H Krum, D Kelly, C Reid.
- Development of new anti-fibrotic drugs for development of diabetic nephropathy (NHMRC Development Grant, 2009 $130,500) D Kelly.
- FT011, directly targeting myocardial fibrosis will improve heart function in experimental model of diabetic cardiomyopathy (DART Ian McEwan Complications Grant, 2009 $59,167) D Kelly.
- Senior Research Fellowship (NHMRC Research Fellowship SRF A, 2009 – 2013, $560,000) D Kelly.
Selected Publications
- Kelly, D.J., Buck, D., Zhang, Y., Cox, A.J. and Gilbert, R.E. (2007) Effects of protein kinase C-ß inhibition on glomerular endothelial cells in advanced experimental diabetic nephropathy. Am J Physiology (Renal) 293(2):F565-F574. IF = 4.199 (0)
- Kelly, D.J., Zhang, Y., Moe, G., Naik, G. and Gilbert, R.E. (2007) Aliskiren, a novel renin inhibitor, is renoprotective in advanced diabetic nephropathy in rats. Diabetologia 50(11):2398-2404. IF = 5.247 (0)
- Kelly, D.J., Zhang, Y., Connelly, K., Cox, A.J., Martin, J., Krum, H. and Gilbert, R.E. (2007) Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol (Heart and Circulation) 293(5):H2860-2869. IF = 3.724 (0).
- Advani, A., Gilbert, R.E., Thai, K., Gow, R.M., Langham, R.G., Cox, A.J., Zhang, Y., Connelly, K.A., Herzenberg, A., Christensen, P.K., Pollock, C.A., Parving, H-H, and Kelly, D.J. (2009). Expression, Localization, and Function of the Thioredoxin System in Diabetic Nephropathy. J Am Soc Nephrology 20(4):730-741.
- Kelly, D.J., Edgley, A.J., Zhang, Y., Thai, K., Advani, A., Connelly, K.A., Whiteside, C.I. and Gilbert, R.E. (2009) Protein kinase C-ß inhibition attenuates the progression of nephropathy in the non diabetic kidney disease. Nephrol Dial Transplant. 1460-2385
- Advani, A., Kelly, D.J., Cox, A.J., White, K.E., Advani, S.L., Thai, K., Connelly, K.A., Yuen, D., Trogadis, J., Herzenberg, A.M., Kuliszewski, M.A., Leong-Poi, H. and Gilbert, R.E. (2009). The prorenin receptor colocalizes with the vaculoar H+ATPase in the distal nephron. Hypertension . epub Jun 2009.
- full list of publications
Patents
- Co-inventor on WO2001/064200. "Use of N-Phenyl-2-pyrimidine-amine Derivatives for the Treatment of Nephropathy, Glomerulonephritis and Chronic Pyelonephritis" with Novartis Pharmaceuticals (2001).
- Co-inventor on WO2003/077892. Use of GLIVEC for the treatment of Ang II-mediated diseases (e.g. diseases involving angiotensin II induced hypertrophy (2003).
- PCT/AU2007/000934 "Therapeutic Compuonds" (2006, licensed to Fibrotech)
- PCT/AU2007/000343 "Compositions and therapies using tranilast compounds" (2007, licensed to Fibrotech).
- PCT/AU2008/000576 "Treatment of mesangial proliferative diseases" (licensed to Fibrotech)
- Provisional Patent (Filed Dec 2007, licensed to Fibrotech) Analogues of anti-fibrotic agents I. File #61/016,120
- PCT/AU2008/001868 "Halogenated analogues of anti-fibrotic agents" (licensed to Fibrotech)